Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients

Abstract

Adipocyte fatty acid binding protein (A-FABP) has been reported to be involved in insulin resistance, lipid metabolism, and atherosclerosis; however, little is known about the effect of medication on the change in circulating A-FABP in human subjects. We evaluated the effects of angiotensin II type 1 receptor blocker (ARB) on arterial stiffness and its association with serum A-FABP in patients with hypertension. Thirty patients newly diagnosed with essential hypertension were treated with olmesartan (20 mg/day), an ARB, for 6 months. Serum levels of A-FABP and high-sensitivity C-reactive protein (hsCRP) were examined and the cardio-ankle vascular index (CAVI), which is a marker of arterial stiffness, was also determined. Serum A-FABP at baseline was significantly correlated with the body mass index (r = 0.45, P = 0.01), homeostasis model assessment as a marker of insulin resistance (r = 0.53, P < 0.01), and systolic blood pressure (r = 0.37, P = 0.047), and tended to be correlated with low-density lipoprotein cholesterol, triglyceride, and CAVI. Olmesartan treatment resulted in a significant decrease in CAVI, serum A-FABP levels, and hsCRP, besides a significant reduction of blood pressure. Multiple regression analysis revealed that the change in CAVI was independently correlated with the change in serum A-FABP. Olmesartan ameliorated arterial stiffness in patients with hypertension, which may be involved in the reduction of serum A-FABP.

Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus

“…First, the number of subjects enrolled in study 1 was small, and the possibility of type 1 error in statistical tests cannot be excluded. Second, most of the study subjects had been treated with several drugs at baseline, including angiotensin II receptor blockers ( 33,49 ) and a statin ( 50 ), which have been reported to affect circulating FABP4 concentration. Therefore, such drugs might have modulated the change in FABP4 level.…”

Negative Impact of Cardiovascular Risk Factors on Left Atrial and Left Ventricular Function Related to Aortic Stiffness

“…Therefore, early intervention with angiotensin II receptor blockers and statins seems to have beneficial effects on abnormalities in structure and function of the LA, LV, and aorta in this type of patient. [30][31][32][33] …”

The Effects of Antihypertensive Agents in Metabolic Syndrome – Benefits Beyond Blood Pressure Control

“…In a small study of 10 patients with mild-to-moderate hypertension, olmesartan medoxomil did not reduce BP significantly, but did produce significant reductions in hsCRP and appeared to improve myocardial function independent of BP lowering [19]. In another study, hsCRP levels significantly dropped in hypertensive patients who were treated with olmesartan for 6 month [102]. In nondiabetic patients with hypertension and the metabolic syndrome, both olmesartan medoxomil plus amlodipine and olmesartan medoxomil plus HCTZ effectively reduced BP and CRP with no differences between groups.…”

“…However, arterial index decreased significantly with monotheraphy and combination therapy in this study. On the other hand, another recent study showed that monotheraphy with olmesartan does significantly decrease arterial stiffness [102].…”